Report Detail

Pharma & Healthcare Global Congenital Diaphragmatic Hernia Drug Market Growth 2022-2028

  • RnM4488434
  • |
  • 30 August, 2022
  • |
  • Global
  • |
  • 107 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

The Congenital Diaphragmatic Hernia Drug is a drug for the treatment of congenital diseases that cause a series of symptoms due to the congenital defect in the development of the diaphragmatic muscle, which causes the abdominal organs to herniate into the thoracic cavity.

The global market for Congenital Diaphragmatic Hernia Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Congenital Diaphragmatic Hernia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Congenital Diaphragmatic Hernia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Congenital Diaphragmatic Hernia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Congenital Diaphragmatic Hernia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Congenital Diaphragmatic Hernia Drug players cover B. Braun Melsungen AG, Cousin Biotech, ASPIDE MEDICAL, Bard and WL Gore, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Congenital Diaphragmatic Hernia Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Congenital Diaphragmatic Hernia Drug market, with both quantitative and qualitative data, to help readers understand how the Congenital Diaphragmatic Hernia Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the Congenital Diaphragmatic Hernia Drug market and forecasts the market size by Type (Posterolateral Bochdalek Hernia, Anterior Morgagni Hernia and Hiatal Hernia), by Application (Hospital, Clinic and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Posterolateral Bochdalek Hernia
Anterior Morgagni Hernia
Hiatal Hernia

Segmentation by application
Hospital
Clinic
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
B. Braun Melsungen AG
Cousin Biotech
ASPIDE MEDICAL
Bard
WL Gore
Cook Medical
Maquet
DIPROMED
Integra LifeSciences Corporation
Herniamesh

Chapter Introduction
Chapter 1: Scope of Congenital Diaphragmatic Hernia Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Congenital Diaphragmatic Hernia Drug market size (sales and revenue) and CAGR, Congenital Diaphragmatic Hernia Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Congenital Diaphragmatic Hernia Drug sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Congenital Diaphragmatic Hernia Drug sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Congenital Diaphragmatic Hernia Drug market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including B. Braun Melsungen AG, Cousin Biotech, ASPIDE MEDICAL, Bard, WL Gore, Cook Medical, Maquet, DIPROMED and Integra LifeSciences Corporation, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Congenital Diaphragmatic Hernia Drug Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Congenital Diaphragmatic Hernia Drug by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Congenital Diaphragmatic Hernia Drug by Country/Region, 2017, 2022 & 2028
  • 2.2 Congenital Diaphragmatic Hernia Drug Segment by Type
    • 2.2.1 Posterolateral Bochdalek Hernia
    • 2.2.2 Anterior Morgagni Hernia
    • 2.2.3 Hiatal Hernia
  • 2.3 Congenital Diaphragmatic Hernia Drug Sales by Type
    • 2.3.1 Global Congenital Diaphragmatic Hernia Drug Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Congenital Diaphragmatic Hernia Drug Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Congenital Diaphragmatic Hernia Drug Sale Price by Type (2017-2022)
  • 2.4 Congenital Diaphragmatic Hernia Drug Segment by Application
    • 2.4.1 Hospital
    • 2.4.2 Clinic
    • 2.4.3 Others
  • 2.5 Congenital Diaphragmatic Hernia Drug Sales by Application
    • 2.5.1 Global Congenital Diaphragmatic Hernia Drug Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Congenital Diaphragmatic Hernia Drug Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Congenital Diaphragmatic Hernia Drug Sale Price by Application (2017-2022)

3 Global Congenital Diaphragmatic Hernia Drug by Company

  • 3.1 Global Congenital Diaphragmatic Hernia Drug Breakdown Data by Company
    • 3.1.1 Global Congenital Diaphragmatic Hernia Drug Annual Sales by Company (2020-2022)
    • 3.1.2 Global Congenital Diaphragmatic Hernia Drug Sales Market Share by Company (2020-2022)
  • 3.2 Global Congenital Diaphragmatic Hernia Drug Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Congenital Diaphragmatic Hernia Drug Revenue by Company (2020-2022)
    • 3.2.2 Global Congenital Diaphragmatic Hernia Drug Revenue Market Share by Company (2020-2022)
  • 3.3 Global Congenital Diaphragmatic Hernia Drug Sale Price by Company
  • 3.4 Key Manufacturers Congenital Diaphragmatic Hernia Drug Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Congenital Diaphragmatic Hernia Drug Product Location Distribution
    • 3.4.2 Players Congenital Diaphragmatic Hernia Drug Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Congenital Diaphragmatic Hernia Drug by Geographic Region

  • 4.1 World Historic Congenital Diaphragmatic Hernia Drug Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Congenital Diaphragmatic Hernia Drug Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Congenital Diaphragmatic Hernia Drug Annual Revenue by Geographic Region
  • 4.2 World Historic Congenital Diaphragmatic Hernia Drug Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Congenital Diaphragmatic Hernia Drug Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Congenital Diaphragmatic Hernia Drug Annual Revenue by Country/Region
  • 4.3 Americas Congenital Diaphragmatic Hernia Drug Sales Growth
  • 4.4 APAC Congenital Diaphragmatic Hernia Drug Sales Growth
  • 4.5 Europe Congenital Diaphragmatic Hernia Drug Sales Growth
  • 4.6 Middle East & Africa Congenital Diaphragmatic Hernia Drug Sales Growth

5 Americas

  • 5.1 Americas Congenital Diaphragmatic Hernia Drug Sales by Country
    • 5.1.1 Americas Congenital Diaphragmatic Hernia Drug Sales by Country (2017-2022)
    • 5.1.2 Americas Congenital Diaphragmatic Hernia Drug Revenue by Country (2017-2022)
  • 5.2 Americas Congenital Diaphragmatic Hernia Drug Sales by Type
  • 5.3 Americas Congenital Diaphragmatic Hernia Drug Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Congenital Diaphragmatic Hernia Drug Sales by Region
    • 6.1.1 APAC Congenital Diaphragmatic Hernia Drug Sales by Region (2017-2022)
    • 6.1.2 APAC Congenital Diaphragmatic Hernia Drug Revenue by Region (2017-2022)
  • 6.2 APAC Congenital Diaphragmatic Hernia Drug Sales by Type
  • 6.3 APAC Congenital Diaphragmatic Hernia Drug Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Congenital Diaphragmatic Hernia Drug by Country
    • 7.1.1 Europe Congenital Diaphragmatic Hernia Drug Sales by Country (2017-2022)
    • 7.1.2 Europe Congenital Diaphragmatic Hernia Drug Revenue by Country (2017-2022)
  • 7.2 Europe Congenital Diaphragmatic Hernia Drug Sales by Type
  • 7.3 Europe Congenital Diaphragmatic Hernia Drug Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Congenital Diaphragmatic Hernia Drug by Country
    • 8.1.1 Middle East & Africa Congenital Diaphragmatic Hernia Drug Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Congenital Diaphragmatic Hernia Drug Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Congenital Diaphragmatic Hernia Drug Sales by Type
  • 8.3 Middle East & Africa Congenital Diaphragmatic Hernia Drug Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Congenital Diaphragmatic Hernia Drug
  • 10.3 Manufacturing Process Analysis of Congenital Diaphragmatic Hernia Drug
  • 10.4 Industry Chain Structure of Congenital Diaphragmatic Hernia Drug

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Congenital Diaphragmatic Hernia Drug Distributors
  • 11.3 Congenital Diaphragmatic Hernia Drug Customer

12 World Forecast Review for Congenital Diaphragmatic Hernia Drug by Geographic Region

  • 12.1 Global Congenital Diaphragmatic Hernia Drug Market Size Forecast by Region
    • 12.1.1 Global Congenital Diaphragmatic Hernia Drug Forecast by Region (2023-2028)
    • 12.1.2 Global Congenital Diaphragmatic Hernia Drug Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Congenital Diaphragmatic Hernia Drug Forecast by Type
  • 12.7 Global Congenital Diaphragmatic Hernia Drug Forecast by Application

13 Key Players Analysis

  • 13.1 B. Braun Melsungen AG
    • 13.1.1 B. Braun Melsungen AG Company Information
    • 13.1.2 B. Braun Melsungen AG Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.1.3 B. Braun Melsungen AG Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 B. Braun Melsungen AG Main Business Overview
    • 13.1.5 B. Braun Melsungen AG Latest Developments
  • 13.2 Cousin Biotech
    • 13.2.1 Cousin Biotech Company Information
    • 13.2.2 Cousin Biotech Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.2.3 Cousin Biotech Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 Cousin Biotech Main Business Overview
    • 13.2.5 Cousin Biotech Latest Developments
  • 13.3 ASPIDE MEDICAL
    • 13.3.1 ASPIDE MEDICAL Company Information
    • 13.3.2 ASPIDE MEDICAL Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.3.3 ASPIDE MEDICAL Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 ASPIDE MEDICAL Main Business Overview
    • 13.3.5 ASPIDE MEDICAL Latest Developments
  • 13.4 Bard
    • 13.4.1 Bard Company Information
    • 13.4.2 Bard Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.4.3 Bard Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Bard Main Business Overview
    • 13.4.5 Bard Latest Developments
  • 13.5 WL Gore
    • 13.5.1 WL Gore Company Information
    • 13.5.2 WL Gore Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.5.3 WL Gore Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 WL Gore Main Business Overview
    • 13.5.5 WL Gore Latest Developments
  • 13.6 Cook Medical
    • 13.6.1 Cook Medical Company Information
    • 13.6.2 Cook Medical Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.6.3 Cook Medical Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Cook Medical Main Business Overview
    • 13.6.5 Cook Medical Latest Developments
  • 13.7 Maquet
    • 13.7.1 Maquet Company Information
    • 13.7.2 Maquet Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.7.3 Maquet Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Maquet Main Business Overview
    • 13.7.5 Maquet Latest Developments
  • 13.8 DIPROMED
    • 13.8.1 DIPROMED Company Information
    • 13.8.2 DIPROMED Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.8.3 DIPROMED Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 DIPROMED Main Business Overview
    • 13.8.5 DIPROMED Latest Developments
  • 13.9 Integra LifeSciences Corporation
    • 13.9.1 Integra LifeSciences Corporation Company Information
    • 13.9.2 Integra LifeSciences Corporation Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.9.3 Integra LifeSciences Corporation Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 Integra LifeSciences Corporation Main Business Overview
    • 13.9.5 Integra LifeSciences Corporation Latest Developments
  • 13.10 Herniamesh
    • 13.10.1 Herniamesh Company Information
    • 13.10.2 Herniamesh Congenital Diaphragmatic Hernia Drug Product Offered
    • 13.10.3 Herniamesh Congenital Diaphragmatic Hernia Drug Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Herniamesh Main Business Overview
    • 13.10.5 Herniamesh Latest Developments

14 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Congenital Diaphragmatic Hernia Drug. Industry analysis & Market Report on Congenital Diaphragmatic Hernia Drug is a syndicated market report, published as Global Congenital Diaphragmatic Hernia Drug Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Congenital Diaphragmatic Hernia Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,315.96
6,631.92
3,733.20
7,466.40
528,796.80
1,057,593.60
298,692.60
597,385.20
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report